RO.CH

301.2

+0.33%↑

NOVN.CH

105.42

+0.9%↑

LONN.CH

547

+1.11%↑

STMN.CH

88.36

+0.52%↑

BANB.CH

58.1

-1.61%↓

RO.CH

301.2

+0.33%↑

NOVN.CH

105.42

+0.9%↑

LONN.CH

547

+1.11%↑

STMN.CH

88.36

+0.52%↑

BANB.CH

58.1

-1.61%↓

RO.CH

301.2

+0.33%↑

NOVN.CH

105.42

+0.9%↑

LONN.CH

547

+1.11%↑

STMN.CH

88.36

+0.52%↑

BANB.CH

58.1

-1.61%↓

RO.CH

301.2

+0.33%↑

NOVN.CH

105.42

+0.9%↑

LONN.CH

547

+1.11%↑

STMN.CH

88.36

+0.52%↑

BANB.CH

58.1

-1.61%↓

RO.CH

301.2

+0.33%↑

NOVN.CH

105.42

+0.9%↑

LONN.CH

547

+1.11%↑

STMN.CH

88.36

+0.52%↑

BANB.CH

58.1

-1.61%↓

Search

Sandoz Group AG

Open

46.29 1.8

Overview

Share price change

24h

Current

Min

45.14

Max

46.47

Key metrics

By Trading Economics

Income

526M

377M

Sales

1.2B

5.3B

P/E

Sector Avg

114.146

35.739

EPS

0.87

Dividend yield

1.39

Profit margin

7.16

Employees

20,000

EBITDA

475M

602M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+11.6% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.39%

3.08%

Next Earnings

30 Oct 2025

Market Stats

By TradingEconomics

Market Cap

-659M

20B

Previous open

44.49

Previous close

46.29

Sandoz Group AG Chart

Past performance is not a reliable indicator of future results.

Related News

28 Jul 2025, 10:51 UTC

Market Talk

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

15 Apr 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

17 Dec 2024, 07:45 UTC

Market Talk

Sandoz's U.S. Settlement to Cost 1.1 Swiss Francs a Share -- Market Talk

17 Dec 2024, 07:34 UTC

Market Talk

Sandoz's U.S. Settlement Shows Commitment Move Forward -- Market Talk

10 Dec 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Peer Comparison

Price change

Sandoz Group AG Forecast

Price Target

By TipRanks

11.6% upside

12 Months Forecast

Average 49.898 CHF  11.6%

High 55 CHF

Low 42.6 CHF

Based on 8 Wall Street analysts offering 12 month price targets forSandoz Group AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

5

Buy

3

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sandoz Group AG

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
help-icon Live chat